<DOC>
	<DOCNO>NCT00147212</DOCNO>
	<brief_summary>The main purpose study find effect ( good bad ) trabectedin ( ET743 ) men advance prostate carcinoma .</brief_summary>
	<brief_title>ET 743 ( Yondelis ) Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>- Treatment trabectedin give week three consecutive week one week treatment . This four week period constitute one cycle . - Trabectedin give infusion central venous catheter administer 3 hour . - On day 1 cycle history , physical exam blood test perform trabectedin administer . - On day 8 day 15 cycle blood work perform trabectedin administer . - Patients continue receive trabectedin long disease progression unacceptable side effect . - Scans ( CT , MRI bone ) x-ray may do patient trial discretion physician .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Radiographically document metastatic disease Surgical chemical castration Prostate specific antigen ( PSA ) &gt; 5 ng/ml Castration resistant prostate cancer ( CRPC ) One previous taxanebased chemotherapy regimen Eastern Cooperative Group ( ECOG ) performance status 0,1 2 Neutrophil count &gt; 1,500/ul Platelet count &gt; 100,000/ul Serum bilirubin &lt; 1.0 x upper limit normal ( ULN ) Serum alkaline phosphatase &lt; 1.5 x ULN Asparate aminotransferase/Alanine aminotransferase &lt; 2.5 x ULN Albumin &gt; 2.5 g/dl Serum creatinine &lt; 1.5 x ULN Prior hormonal therapy Chemotherapy treatment within 4 week study entry Patient employ adequate contraception Serious illness medical condition , specifically : uncontrolled congestive heart failure history myocardial infection active angina pectoris within 6 month ; active infectious process ; chronic active liver disease , include chronic hepatitis B , C cirrhosis Current anticancer treatment nonFDA approve investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>ET 743</keyword>
	<keyword>Yondelis</keyword>
</DOC>